Company Overview

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, and commercializing prescription products that address unmet medical needs. The company operates primarily within the pharmaceuticals and healthcare industry, with an emphasis on niche therapeutic areas where it can leverage targeted sales, regulatory expertise, and partner-driven development. Its business model centers on late-stage or already-approved products, reducing early-stage development risk.

The company was incorporated in 2013 and is headquartered in Vancouver, Canada. Since inception, Aequus has evolved from an early-stage specialty pharma company into a commercial-stage organization with a portfolio strategy based on regional licensing, co-development, and commercialization partnerships. Its positioning is defined by a capital-efficient approach, reliance on external manufacturing and development partners, and a focus on products with defined regulatory pathways.

Business Operations

Aequus operates through a single primary business segment: Specialty Pharmaceuticals, which encompasses product acquisition, regulatory management, commercialization, and lifecycle management. Revenue is generated through product sales in licensed territories, milestone payments, and, where applicable, royalty arrangements. The company does not operate manufacturing facilities and instead relies on third-party manufacturers and development partners.

Key assets in Aequus’ portfolio include Vistitan® (latanoprost ophthalmic solution), licensed for commercialization in Canada for the treatment of glaucoma, and Zymed® PF (prednisolone acetate ophthalmic suspension), a preservative-free corticosteroid used post-ocular surgery. Aequus has also pursued ophthalmology and central nervous system-focused assets, reflecting its strategy of targeting specialized prescriber markets with limited competition.

Strategic Position & Investments

Aequus’ strategic direction emphasizes portfolio expansion through in-licensing agreements, particularly for products that are approved or near approval in other jurisdictions. Growth initiatives focus on expanding commercial execution in Canada while selectively pursuing additional international rights when supported by partners. The company has historically prioritized ophthalmology as a core area due to predictable prescribing patterns and defined reimbursement frameworks.

The company has entered into multiple licensing and collaboration agreements with international pharmaceutical firms to access differentiated products without assuming full development risk. While Aequus does not maintain a broad investment portfolio or numerous subsidiaries, its strategy relies on contractual rights to commercialize partnered assets rather than outright acquisitions. Public disclosures indicate no large-scale acquisitions; growth has primarily been partnership-driven.

Geographic Footprint

Aequus’ operations are primarily concentrated in Canada, which represents its principal commercial market and regulatory focus. The company’s headquarters are located in Vancouver, British Columbia, and its sales and regulatory activities are aligned with Canadian healthcare systems and payer structures.

Internationally, Aequus maintains an indirect presence through licensing relationships with partners based in Europe and Asia, where certain products originate or are manufactured. These relationships provide exposure to global pharmaceutical development without direct operational infrastructure outside Canada.

Leadership & Governance

Aequus is led by a management team with experience in pharmaceuticals, biotechnology, and capital markets. The leadership emphasizes disciplined capital allocation, partnership-driven growth, and a focus on commercially viable assets rather than high-risk discovery programs.

Key executives include:

• Doug Janzen – Chief Executive Officer
• Andrew Rollins – Chief Financial Officer
• Nick DeMasi – Chairman of the Board

The company is governed by a board of directors with backgrounds in healthcare, finance, and public company governance. Leadership communications and public disclosures consistently highlight a strategy centered on risk-managed growth, operational efficiency, and shareholder value creation within the specialty pharmaceutical sector.